Good price  online

products details

Created with Pixso. Home Created with Pixso. Products Created with Pixso.
Oncology Drugs
Created with Pixso. Mirdametinib LuciMird Oncology Drugs To Treat Neurofibromatosis

Mirdametinib LuciMird Oncology Drugs To Treat Neurofibromatosis

Brand Name: Lucius Pharmaceuticals
Model Number: Mirdametinib Capsules Lu-0325901
MOQ: 1 PCS
Price: Please contact a specialist WhatsApp:55342706
Delivery Time: Negotiable
Payment Terms: Western Union, , T/T
Detail Information
Place of Origin:
Vientiane, Laos
Certification:
Registered certificate issued by Laos Food and Drug Administration, GMP certification; the original drug is approved by US FDA
Specification::
2mg*60 Capsules/bottle (box)
Indications::
Plexiform Neurofibroma, NRAS-mutated Melanoma, RAS-driven Solid Tumors
Target::
MEK1/2
Product Name::
Mirdametinib
Recommended::
Please Follow Doctor's Advice
Storage::
Sealed And Stored Below 25℃, Avoid Light
Packaging Details:
Negotiable
Supply Ability:
Negotiable
Highlight:

LuciMird Mirdametinib Neurofibromatosis Type 1

,

Generic Gomekli Mirdametinib Plexiform Neurofibromas

,

Lucius PD-0325901 MEK Inhibitor Oncology Drug

Product Description

LuciMird Mirdametinib Capsules — Brief Overview

For use only under professional medical guidance.
Trade name: LuciMird
 
Manufacturer: Lao Lucius Health Products Co., Ltd.
 
Chinese name: Mirdametinib Capsules
 
English name: Mirdametinib Capsules
 
Registration serial number: 03-LM-01455-26

Indications

LuciMird is a kinase-modulating agent indicated for adults and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas that cannot be completely resected by surgery.

Administration

The recommended dose of LuciMird is 2 mg/m² orally twice daily for 21 consecutive days (the first 21 days of each 28-day cycle), taken with or without food. Continue LuciMird until disease progression or unacceptable toxicity occurs.

Product Specification

Each tablet contains 1 mg; 42 tablets per box.

Limitation of Use

None

Important Notes and Monitoring Points

  • Risk of ocular disorders: A comprehensive eye examination should be performed before starting LuciMird, at regular intervals during treatment, and whenever new or worsening visual changes or blurred vision occur. Depending on the severity of symptoms, decide whether to continue, interrupt, reduce the dose, or permanently discontinue LuciMird.
  • Decreased left ventricular pumping function: An echocardiogram should be performed before taking LuciMird to assess ejection fraction, then every 3 months during the first year of treatment, and thereafter as clinically indicated. Depending on the severity of symptoms, interrupt dosing, reduce the dose, or permanently discontinue LuciMird.
  • Abnormal skin reactions: Once early skin symptoms, including skin redness and rash, appear, soothing care should be initiated immediately. Depending on severity, interrupt dosing, reduce the dose, or permanently discontinue LuciMird.
  • Risk to fetal development: May cause harm to the unborn baby. Women of childbearing potential should be informed of the potential risk to the baby, and reliable contraception should be recommended.

Adverse Reactions Following Administration

Adult patients

  • Most common adverse reactions (incidence >25%): rash, diarrhea, nausea, musculoskeletal pain, vomiting, and fatigue.
  • Most common grade 3 or 4 laboratory abnormalities (incidence >2%): increased creatine phosphokinase.

Pediatric patients

  • Most common adverse reactions (incidence >25%): rash, diarrhea, musculoskeletal pain, abdominal pain, vomiting, headache, paronychia, decreased left ventricular pumping function, and nausea.
  • Most common grade 3 or 4 laboratory abnormalities (incidence >2%): decreased neutrophil count and increased creatine phosphokinase.

Instructions for Special Populations

  • Lactation: Breastfeeding is not recommended.
  • Effects on fertility: May affect female reproductive ability.

Storage Rules

Store at 20°C to 25°C (68°F to 77°F); temperature fluctuations between 15°C and 30°C (59°F to 86°F) are acceptable for short-distance transport. Keep away from moisture.